Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Profit After Tax: 2016-2025

Historic Profit After Tax for UroGen Pharma (URGN) over the last 10 years, with Sep 2025 value amounting to -$33.3 million.

  • UroGen Pharma's Profit After Tax fell 40.87% to -$33.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$164.6 million, marking a year-over-year decrease of 42.70%. This contributed to the annual value of -$126.9 million for FY2024, which is 24.09% down from last year.
  • UroGen Pharma's Profit After Tax amounted to -$33.3 million in Q3 2025, which was up 33.23% from -$49.9 million recorded in Q2 2025.
  • UroGen Pharma's 5-year Profit After Tax high stood at -$21.9 million for Q3 2023, and its period low was -$49.9 million during Q2 2025.
  • Moreover, its 3-year median value for Profit After Tax was -$32.3 million (2024), whereas its average is -$32.4 million.
  • Per our database at Business Quant, UroGen Pharma's Profit After Tax skyrocketed by 30.62% in 2021 and then crashed by 49.51% in 2025.
  • UroGen Pharma's Profit After Tax (Quarterly) stood at -$28.5 million in 2021, then decreased by 1.47% to -$28.9 million in 2022, then climbed by 9.88% to -$26.0 million in 2023, then tumbled by 44.19% to -$37.5 million in 2024, then plummeted by 40.87% to -$33.3 million in 2025.
  • Its last three reported values are -$33.3 million in Q3 2025, -$49.9 million for Q2 2025, and -$43.8 million during Q1 2025.